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Abstract 30 
 Human skin remains the membrane of choice when conducting in vitro studies to determine 31 
dermal penetration of active pharmaceutical ingredients or xenobiotics. However there are ethical and 32 
safety issues associated with obtaining human tissue. For these reasons synthetic membranes, cell 33 
culture models or in silico predictive algorithms have been researched intensively as alternative 34 
approaches to predict dermal exposure in man. Porcine skin has also been recommended as an 35 
acceptable surrogate for topical or transdermal delivery research. Here we examine the in vitro 36 
permeation of a model active, ibuprofen, using human or porcine skin, as well as the Parallel Artificial 37 
Membrane Permeation Assay (PAMPA) model and silicone membrane. Finite dose studies were 38 
conducted in all models using commercial ibuprofen formulations and simple volatile ibuprofen 39 
solutions. The dose applied in the PAMPA model was also varied in order to determine the amount of 40 
applied formulation which best simulates typical amounts of topical products applied by patients or 41 
consumers. Permeation studies were conducted up to 6 h for PAMPA and silicone and up to 48 h for 42 
human and porcine skin. Cumulative amounts permeated at 6 h were comparable for PAMPA and 43 
silicone, ranging from 91–136 g/cm2 across the range of formulations studied. At 48 h, maximum 44 
ibuprofen permeation in human skin ranged from 11–38 g/cm2 and corresponding values in porcine 45 
skin were 59–81 g/cm2. A dose of 1 l/cm2 was confirmed as appropriate for finite dose studies in the 46 
PAMPA model. The formulation which delivered the greatest amount of ibuprofen in human skin was 47 
also significantly more efficient than other formulations when evaluated in the PAMPA model. The 48 
PAMPA model also discriminated between different formulation types (i.e. gel versus solution) 49 
compared with other models. Overall, the results confirm the more permeable nature of the PAMPA, 50 
silicone membrane and porcine tissue models to ibuprofen compared with human skin. Further finite 51 
dose studies to elucidate the effects of individual excipients on the barrier properties of the PAMPA 52 
model are needed to expand the applications of this model. The range of actives that are suitable for 53 
study using the model also needs to be delineated.  54 
 55 
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Introduction  64 
 Assessment of skin penetration of actives is of critical importance in a number of fields. Effective 65 
active pharmaceutical ingredient (API) permeation is required for therapeutic benefits, knowledge of 66 
the skin disposition of pesticides is important for human health and quantitation of delivery of cosmetic 67 
actives to the skin provides confidence for product claim support. Many different models of human skin 68 
have been proposed in order to quantify and predict percutaneous penetration. This reflects the 69 
difficulties in sourcing tissue as well as ethical issues and safety concerns associated with biological 70 
membranes. Early models of mass transfer in skin focussed on apparatus such as the rotating diffusion 71 
cell which employed isopropyl myristate (IPM) impregnated in filter paper as a surrogate skin lipid phase 72 
(Albery et al., 1976). Other lipids which have been used to model skin penetration include tetradecane, 73 
linoleic acid and dispersions of phospholipids in IPM (Guy and Fleming, 1979). Interestingly, eggshell 74 
membranes impregnated with IPM were considered by Washitake et al., (1980); removal of the shell 75 
with hydrochloric acid leaves a predominantly keratin rich membrane. With advances in knowledge of 76 
the composition of skin lipids more realistic mixtures of phosphatidyl choline, dipalmitoyl phosphatidly 77 
choline, ceramides, cholesterol, cholesterol palmitate, linoleic acid and tristearin were later investigated 78 
(Firestone and Guy, 1985).  79 
In vitro permeation studies have also been conducted with simple polymeric membranes such 80 
as polydimethylsiloxane (Dias et al., 2007; Santos et al., 2009; Oliveira et al., 2012). While these studies 81 
are useful to probe thermodynamic activity of actives in specific formulations, they cannot provide any 82 
insight into specific excipient interactions with skin. The advent of tissue culture models for research 83 
applications stimulated much interest in the development of human skin equivalents (HSEs). 84 
Subsequently a number of models have become available including Epiderm™, Episkin™ and Labskin™. 85 
Typically these HSEs are based on cultures of normal human keratinocytes and/or fibroblasts and are 86 
metabolically and mitotically active. Although HSEs are reported to over-estimate likely permeation in 87 
human skin (Schmook et al., 2001; Basketter et al., 2007; Thakoersing et al., 2012; Labouta et al., 2013;) 88 
they are routinely used for toxicity and/or irritation testing (Spielmann et al., 2007; Alépée et al., 2014).  89 
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Recently, the Parallel Artificial Membrane Permeation Assay (PAMPA) has been proposed as a 90 
high throughput screening system that may be suitable to study skin permeation (Sinkó et al., 2012). 91 
Previously the PAMPA model was investigated for prediction of gastrointestinal absorption (Avdeef and 92 
Tsinman, 2006; Avdeef et al., 2007) and as a potential model of the blood-brain barrier (Tsinman et al., 93 
2011). This model consists of a mixture of synthetic ceramides (certamides), cholesterol and free fatty 94 
acids mounted in 96-well plates (Sinkó et al., 2012). With respect to skin permeation the number of 95 
molecules and formulations evaluated in PAMPA to date remains low. Accordingly we set out to 96 
examine the permeation of a model API, ibuprofen, from two commercial preparations and two simple 97 
solutions using the PAMPA model. The data are compared with results from studies conducted with an 98 
artificial membrane (silicone) as well as with porcine and human skin. A further objective was to identify 99 
optimal dosing in the PAMPA model which best simulates typical amounts applied on skin by patients 100 
and consumers.  101 
Ibuprofen was a gift from Wyeth (Haversham, Hants., UK). Polyethylene glycol (PEG) 300, 102 
propylene glycol (PG), HPLC grade isopropyl alcohol and trifluoroacetic acid (HPLC grade) were supplied 103 
by Fisher Scientific (UK). HPLC grade solvents (methanol and water) were provided by Sigma-Aldrich (UK). 104 
Phosphate buffered saline (pH 7.4) was prepared using Dulbecco A tablets (Oxoid, UK). Silicone 105 
membrane (250 m) was obtained from Samco (Nuneaton, UK). This grade and thickness of silicone was 106 
selected because we have used it previously to examine the effects of a range of hydrophilic and 107 
lipophilic vehicles on ibuprofen permeation (Watkinson et al., 2009a,b; Watkinson et al., 2011). The pre-108 
coated Skin PAMPA Sandwich stirring disks, hydration solution, and Gut-Box™ were obtained from pION 109 
Inc. (Billerica, USA). Porcine tissue was obtained from a local abattoir. Excised abdominal human skin 110 
was obtained from the UK Human Tissue Bank and was stored in a freezer at -20oC until required 111 
(Research Ethics Committee reference 06/MRE04/37). The commercial formulations selected for 112 
evaluation were IBUGEL™ (Ibuprofen 5% w/w) and IBULEVE™ Speed Relief 5% Spray (Dermal 113 
Laboratories, Hitchin, Hertfordshire, UK). Two other formulations of ibuprofen were prepared as 5% 114 
w/w solutions in isopropyl alcohol and either PEG 300 or PG.  115 
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Silicone membrane was pre-treated as reported previously (Oliveira et al., 2012). Full-thickness 116 
porcine ear skin was prepared as described by Caon et al. (2010) and stored at -20°C until required. 117 
Heat-separated epidermis was obtained from human skin samples (Oliveira et al., 2012). Silicone and 118 
tissues were mounted between donor and receptor compartments of Franz cells (effective diffusion 119 
area ~1 cm2). Assembled Franz cells were filled with PBS pH 7.4 which served as the receptor phase and 120 
0.02% sodium azide (w/v) was also included in the receptor phase for studies that lasted for 48 h. All 121 
permeation studies were conducted at 32±1°C as confirmed with a Digitron TM-22 Differential Digital 122 
Thermometer, (RS Components, Corby, UK). Formulations were dosed at volumes of either 3.6 L 123 
(solutions) or 4 L (gel) in each Franz cell. Samples (200 L) were removed from the receptor 124 
compartment at regular intervals over the duration of the permeation studies and replaced with fresh 125 
receptor phase. Experiments were conducted in silicone membrane and PAMPA for 6 h as preliminary 126 
studies had confirmed that most of the API had permeated by this time point.  127 
The Skin PAMPA membrane was hydrated overnight by placing 200 µL of the hydration solution 128 
in each well. For these studies, three different doses were investigated in order to determine the 129 
amount of formulation which best represented finite dose conditions. Following removal of the 130 
hydration solution, 1, 3, or 30 µL of the tested formulations were applied by a Multipette® plus pipette 131 
(Eppendorf AG, Germany) on the membrane surface in each well of the top (donor) compartment of the 132 
PAMPA Sandwich. This corresponds to a dose of 3.3, 9.9 and 99 µL/cm2. The corresponding wells in each 133 
bottom (receptor) plate were prefilled with 180 µL of PBS pH 7.4 and a stirring disk was also placed in 134 
each well. Subsequently, the PAMPA Sandwich was incubated on the stirring unit or “Gut-BoxTM” at 135 
32±1oC. At 0.5, 1, 2, 3, 4 and 6 h, the bottom (receptor) plate was replaced with a plate prefilled with 136 
fresh receptor phase and stirrer disks. Replacing the entire receptor phase and a shorter interval 137 
between sample times compared with Franz cell studies was necessary in order to maintain sink 138 
conditions.  139 
PAMPA samples were analysed using a Hewlett-Packard HPLC 1100 series equipped with a diode 140 
array detector. Separation was conducted at 30°C using a Luna C18 column (250×4.6 mm, 5 µm 141 
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stationary phase) fitted with a 4 mm C18 guard cartridge (Phenomenex Ltd., USA). The mobile phase 142 
consisted of methanol:water (80:20) with 0.1% (v/v) trifluoroacetic acid (TFA) and the flow rate was 1 143 
mL/min. The wavelength employed was 222 nm and each sample was analysed for 10 min. The 144 
ibuprofen peak eluted at 7 min under these analytical conditions. For studies conducted with silicone 145 
membrane, porcine or human skin a Luna C18 column (200×4.6 mm, 5 µm stationary phase) fitted with 146 
two C18 4×3 mm, 5 µm guard cartridges (Phenomenex Ltd., USA) was used. Analysis was conducted at 147 
35°C, a flow rate of 1 ml/ min and a detection wavelength of 222 nm; the retention time of ibuprofen 148 
under these conditions was 6 min.   149 
All the data were recorded by MS Excel® (Microsoft Corp., USA). The results are shown as mean 150 
± standard deviation (SD). Statistical analysis was performed using MS Excel® and OriginPro® (OriginLab 151 
Corp., USA). One way analysis of variance (ANOVA) followed by a Tukey test was conducted (OriginPro®) 152 
for multiple comparison between the groups (at 5% significance level), p<0.05 was considered as the 153 
statistical significance. 154 
Cumulative amounts of ibuprofen permeated from the various formulations for the four 155 
different models and the corresponding percentages permeated are shown in Figures 1 and 2, 156 
respectively.  157 
 158 
 159 
 160 
 161 
 162 
 163 
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 166 
Figure 1 Cumulative amounts of ibuprofen permeated from IBUGEL® (), IBULEVE® (), PG () and PEG 300 () 167 
for: Human skin (A), Porcine skin (B), Silicone membrane (C) and Skin PAMPA dosed at 1 l/cm
2
 (D). Each data 168 
point represents the mean±SD (n≥5). 169 
 170 
After 6 h, similar amounts of ibuprofen had permeated in silicone membrane and in PAMPA 171 
(~140 g/cm2). For porcine and human skin maximum amounts of permeation were ~80 g/cm2 and ~40 172 
g/cm2 respectively. Typical curvilinear permeation profiles for all formulations were observed with all 173 
the membranes studied (Figure 1). Significantly higher permeation was observed in human skin for the 174 
PG formulation (p<0.05). In Skin PAMPA, significant differences were also found after 6 h when 175 
comparing the PG formulation with IBUGEL® and IBULEVE®. These differences were not observed for the 176 
amounts permeated in porcine skin at any time point nor in silicone membrane at 6 h. The higher 177 
ibuprofen permeation in porcine skin compared with human skin is consistent with data from other 178 
researchers (Dick and Scott, 1992; Singh et al., 2002; Barbero and Frasch, 2009). Both mammalian 179 
tissues had been stored in a freezer (-20oC) until use but a comparison of permeation behaviour in fresh 180 
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human skin and porcine skin would provide a useful insight into whether this storage process has 181 
contributed to the permeation results observed here.  182 
 183 
  184 
   185 
Figure 2 Percentages of ibuprofen permeated from IBUGEL® (), IBULEVE® (), PG () and PEG 300 () for: 186 
Human skin (A), Porcine skin (B), Silicone membrane (C) and Skin PAMPA dosed at 1 l/cm
2
 (D). Each data point 187 
represents the mean±SD (n≥5). 188 
 189 
At 24 h the maximum average percentage permeation of ibuprofen was ~40% in porcine skin 190 
compared with ~4% in human skin, with the exception of the PG formulation in human skin where 20% 191 
of the dose permeated (Figure 2). Although PG is also present in IBUGEL ™, the amount used in the 192 
volatile PG solution has been adjusted to ensure optimal thermodynamic activity of ibuprofen. This 193 
likely explains the superior permeation of ibuprofen from this vehicle and will be reported in a separate 194 
publication (Patel et al., In Press). Comparatively higher percentages of active permeated at 6 h for the 195 
PAMPA and silicone membrane modes (Figure 2) with values ranging from 60-100%. Significantly lower 196 
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amounts of ibuprofen permeated through silicone membrane from the commercial gel formulation at 4 197 
and 6 h compared with all other formulations (p<0.05). 198 
Figure 3 shows cumulative amounts of drug and percentages permeated for three different 199 
doses (1, 3 and 30 µL) of all formulations evaluated in the PAMPA model. 200 
  201 
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 202 
    203 
  204 
    205 
Figure 3 Cumulative amounts of ibuprofen and percentages permeated from IBUGEL® (), IBULEVE® (), PG () 206 
and PEG 300 () in PAMPA following application of 30 µL (A) and (B), 3 µL (C) and (D), and 1 µL (E) and (F) per well. 207 
Each data point represents the mean±SD (n=6). 208 
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For the 30 l applications (Figures 3A, 3B), the profiles are generally linear, consistent with these 209 
amounts representing infinite doses. At 6 h, there are significant differences in ibuprofen permeation 210 
from the two commercial formulations and between the gel and all other formulations (p<0.05), but not 211 
between the PG and PEG 300 formulations. This is in contrast to the finite dose studies conducted in 212 
human skin where no differences in permeation from the commercial formulations were determined. 213 
Overall ibuprofen permeation from the PG and PEG 300 alcoholic solutions is higher than for the 214 
commercial formulations in PAMPA (p<0.05). For human skin studies significantly higher permeation 215 
was only evident for the PG formulation compared with all other formulations. For the commercial 216 
formulations the permeation differences may reflect the influence of various excipients on ibuprofen 217 
permeation. Both formulations contain industrial methylated spirit (IMS) or denatured alcohol. The gel 218 
contains PG whereas the spray does not. The volatile nature of the spray formulation should also result 219 
in a shorter residence time of this formulation on the PAMPA membrane compared with the gel. 220 
Differences between the commercial spray and the simple solutions may also reflect differences in the 221 
absolute content of the volatile components. However, further studies with individual excipients and 222 
the PAMPA lipid mixture will be needed to interpret these data. These specific excipients and the 223 
functions previously proposed for them are detailed in Table 1.  224 
 225 
Table 1: Excipients included in commercial and experimental formulations and proposed 226 
functions reported in the literature 227 
Excipient Functions  
IMS Penetration enhancer*, solvent† 
PEG 300 Solvent‡ 
PG Penetration enhancer, solvent† 
*
Hadgraft et al., (2003); 
†
Lane (2013); 
‡
Rowe et al., 2012 228 
 229 
As expected cumulative amounts of ibuprofen which permeated drop for the 1 and 3 L doses 230 
compared with the 30 l application and there are no differences in the permeation between the 231 
commercial formulations at 6 h. This is consistent with an exaggerated influence of formulation 232 
excipients on membrane transport at the higher 30 L dose. As we have previously noted data from 233 
infinite dose studies may not be extrapolated to finite dose conditions (Santos et al., 2011; Goh and 234 
Lane, 2014; Luo and Lane, 2015; Hadgraft and Lane, 2016). For the 3 L dose, ibuprofen permeation is 235 
significantly (p<0.05) higher from the formulations containing PG and PEG 300 when compared with 236 
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both commercial formulations. However, after the application of 1 µL, only permeation from the PG 237 
formulation is statistically higher (p<0.05) than the commercial formulations. Overall, a greater 238 
percentage of each formulation permeates in the PAMPA model at these lower doses compared with 239 
the 30 L dose. At 6 h approximately 280 g/cm2 of ibuprofen had permeated following application of 3 240 
L doses of the commercial formulations, accounting for 60–70% of the applied dose. For the 1 l 241 
application the cumulative amounts permeated and percentages of ibuprofen delivered were 90–100 242 
g/cm2 and 64-69% respectively. Clearly the amounts permeated for the 1 µL dose approach values for 243 
porcine skin and silicone membrane (Figure 1); however percentage permeation is closest to values for 244 
the silicone membrane.  245 
In summary, a comparative study of ibuprofen permeation was conducted using human and 246 
porcine tissue, a skin PAMPA model and silicone membrane. After 6 h, ibuprofen was generally more 247 
permeable in PAMPA than human skin and PAMPA data were comparable to results in silicone 248 
membrane. For individual formulations permeation is also higher in PAMPA compared with porcine skin. 249 
Much like silicone membrane, the composition of the Skin PAMPA membrane is considered to be 250 
homogeneous and inert. The low variability of results obtained from PAMPA and silicone may be 251 
attributed to these membrane characteristics. With porcine and human skin, the results are naturally 252 
more variable due to the added complexity of biological membranes. Although the time for permeation 253 
studies in PAMPA was not varied, shorter experimental times may be more appropriate considering the 254 
relatively high percentage of ibuprofen permeation in PAMPA. Application conditions in PAMPA which 255 
approach realistic finite dose conditions were confirmed to be 1 l (3.3 l/cm2) however it is important 256 
to note that this may be specific to a particular active. Interestingly, the formulation which 257 
demonstrated the highest delivery in human skin was also the best formulation which performed best 258 
for the 1 l application conditions in PAMPA. The PAMPA model also appears to be more sensitive to 259 
differences in formulation composition i.e. gel versus solution. Further studies expanding the range of 260 
molecules and formulations which may be suitable for screening using PAMPA are currently underway. 261 
This should provide insight into which formulations are best suited to evaluation using this model.  262 
 263 
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